skin cancer
Castle Biosciences Gains New York State Approval for Pittsburgh Laboratory
The company can now serve NY state patients from either of its two facilities, in addition to populations across other US states under its existing CLIA certifications.
Castle Seeks to Dissipate Medicare Concerns as Q2 Revenues Rise 44 Percent
Despite recent reimbursement struggles, the company said it was raising its full-year guidance above its previously estimated $170 million to $180 million.
The company discussed what it believes are compelling new results on the impact of its testing on patient outcomes during a call discussing its Q1 earnings.
DermTech Stock Soars on News of Additional Coverage for Melanoma Detection Test
The molecular diagnostics firm said two payors with 1.2 million members in New York and Hawaii will cover DermTech's noninvasive testing platform.
Tempus, Kartos Therapeutics to Develop CDx for Skin Cancer Therapy
The test will run on Tempus' xT platform and will be used to identify patients with TP53 wild-type Merkel cell carcinoma who may be eligible for treatment with the drug.